These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21474590)

  • 41. Prolonged TSH receptor A subunit immunization of female mice leads to a long-term model of Graves' disease, tachycardia, and cardiac hypertrophy.
    Holthoff HP; Goebel S; Li Z; Faßbender J; Reimann A; Zeibig S; Lohse MJ; Münch G; Ungerer M
    Endocrinology; 2015 Apr; 156(4):1577-89. PubMed ID: 25562617
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Late manifestation of subclinical hyperthyroidism after goitrogenesis in an index patient with a N670S TSH receptor germline mutation masquerading as TSH receptor antibody negative Graves' disease.
    Schaarschmidt J; Paschke S; Özerden M; Jäschke H; Huth S; Eszlinger M; Meller J; Paschke R
    Horm Metab Res; 2012 Dec; 44(13):962-5. PubMed ID: 22763653
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Direct binding of thyrotropin receptor autoantibody to in vitro translated thyrotropin receptor: a comparison to radioreceptor assay and thyroid stimulating bioassay.
    Morgenthaler NG; Hodak K; Seissler J; Steinbrenner H; Pampel I; Gupta M; McGregor AM; Scherbaum WA; Banga JP
    Thyroid; 1999 May; 9(5):466-75. PubMed ID: 10365678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease.
    Schmidt M; Gorbauch E; Dietlein M; Faust M; Stützer H; Eschner W; Theissen P; Schicha H
    Thyroid; 2006 Mar; 16(3):281-8. PubMed ID: 16571091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative Assessment of Female Mouse Model of Graves' Orbitopathy Under Different Environments, Accompanied by Proinflammatory Cytokine and T-Cell Responses to Thyrotropin Hormone Receptor Antigen.
    Berchner-Pfannschmidt U; Moshkelgosha S; Diaz-Cano S; Edelmann B; Görtz GE; Horstmann M; Noble A; Hansen W; Eckstein A; Banga JP
    Endocrinology; 2016 Apr; 157(4):1673-82. PubMed ID: 26872090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A major role for non-major histocompatibility complex genes but not for microorganisms in a novel murine model of Graves' hyperthyroidism.
    Nagayama Y; McLachlan SM; Rapoport B; Niwa M
    Thyroid; 2003 Mar; 13(3):233-8. PubMed ID: 12729471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Blockade of costimulation between T cells and antigen-presenting cells: an approach to suppress murine Graves' disease induced using thyrotropin receptor-expressing adenovirus.
    Chen CR; Aliesky HA; Guo J; Rapoport B; McLachlan SM
    Thyroid; 2006 May; 16(5):427-34. PubMed ID: 16756463
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Animal models of Graves' disease and Graves' orbitopathy.
    Nagayama Y; Nakahara M; Abiru N
    Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):381-6. PubMed ID: 26181432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Attenuation of induced hyperthyroidism in mice by pretreatment with thyrotropin receptor protein: deviation of thyroid-stimulating to nonfunctional antibodies.
    Misharin AV; Nagayama Y; Aliesky HA; Mizutori Y; Rapoport B; McLachlan SM
    Endocrinology; 2009 Aug; 150(8):3944-52. PubMed ID: 19389831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves' disease.
    McLachlan SM; Rapoport B
    Endocrine; 2019 Nov; 66(2):137-148. PubMed ID: 31560118
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel mouse model of Graves' disease: implications for a role of aberrant MHC class II expression in its pathogenesis.
    Shimojo N; Arima T; Yamaguchi K; Kikuoka S; Kohn LD; Kohno Y
    Int Rev Immunol; 2000; 19(6):619-31. PubMed ID: 11129118
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review of Mouse Models of Graves' Disease and Orbitopathy-Novel Treatment by Induction of Tolerance.
    Ungerer M; Faßbender J; Li Z; Münch G; Holthoff HP
    Clin Rev Allergy Immunol; 2017 Apr; 52(2):182-193. PubMed ID: 27368808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interferon-gamma ELISPOT detecting reactivity of T cells to TSH receptor peptides in Graves' disease.
    Côté-Bigras S; Dionne A; Asselin-Mullen P; Leblicq C; Rottembourg D
    Clin Endocrinol (Oxf); 2014 Feb; 80(2):296-300. PubMed ID: 23734883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peptide scanning for thyrotropin receptor T-cell epitopes in mice vaccinated with naked DNA.
    Pichurin P; Schwarz-Lauer L; Braley-Mullen H; Paras C; Pichurina O; Morris JC; Rapoport B; McLachlan SM
    Thyroid; 2002 Sep; 12(9):755-64. PubMed ID: 12481940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines.
    Mullins RJ; Cohen SB; Webb LM; Chernajovsky Y; Dayan CM; Londei M; Feldmann M
    J Clin Invest; 1995 Jul; 96(1):30-7. PubMed ID: 7615799
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gene expression profiles differ markedly in mouse strains that are (or are not) susceptible to hyperthyroidism induced using thyrotropin receptor-expressing adenovirus.
    Chen CR; Abbud R; Wang C; Tan Y; Rapoport B; McLachlan SM
    Thyroid; 2005 Nov; 15(11):1229-37. PubMed ID: 16356085
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Shared and unique susceptibility genes in a mouse model of Graves' disease determined in BXH and CXB recombinant inbred mice.
    McLachlan SM; Aliesky HA; Pichurin PN; Chen CR; Williams RW; Rapoport B
    Endocrinology; 2008 Apr; 149(4):2001-9. PubMed ID: 18162518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Absence of IL-4, and not suppression of the Th2 response, prevents development of experimental autoimmune Graves' disease.
    Dogan RN; Vasu C; Holterman MJ; Prabhakar BS
    J Immunol; 2003 Feb; 170(4):2195-204. PubMed ID: 12574393
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Graves' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C.
    Koizumi S; Mashio Y; Mizuo H; Matsuda A; Matsuya K; Mizumoto H; Ikota A; Beniko M; Iriuda Y
    Intern Med; 1995 Jan; 34(1):58-60. PubMed ID: 7718983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical models of Graves' disease and associated secondary complications.
    Moshkelgosha S; So PW; Diaz-Cano S; Banga JP
    Curr Pharm Des; 2015; 21(18):2414-21. PubMed ID: 25777757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.